Aging as a Program, Not a Breakdown: New Theories Reframe the Biology of Growing Old
核心洞察
A new perspective by João Pedro de Magalhães argues aging is not passive decay but the unwanted continuation of developmental programs that fail to switch off after growth and reproduction end.
The hyperfunction theory, rooted in Mikhail Blagosklonny's "quasi-programs," links evolutionary theory directly to the molecular mechanisms of aging.
Evidence such as rapamycin, reduced growth hormone/IGF-1 signaling, and caloric restriction extending lifespan fits a programmatic rather than purely damage-based model.
A growing body of research is challenging the long-dominant view that aging results simply from the accumulation of molecular damage. Instead, a new perspective piece argues that aging may be the unwanted continuation of biological programs that were supposed to switch off once growth and reproduction were complete.
The study was conducted by João Pedro de Magalhães from the University of Birmingham and published in the journal Aging. De Magalhães contends that aging is not simply decay, but rather a side effect of developmental and growth programs that keep running long after they stop being useful.
The Hyperfunction Theory
The idea at the center of the piece is called the hyperfunction theory of aging. Unlike damage-based models, hyperfunction theory does not treat aging as damage that accumulates passively over a lifetime. Instead, it argues that aging is a side effect of developmental and growth programs that continue operating into adulthood.
"These pathways promote growth and reproduction early in life, when they're genuinely beneficial," the piece explains. "The trouble starts later, when the same pathways stay switched on into adulthood and start causing harm instead of good."
De Magalhães traces this line of thinking back to the nineteenth century, including Clive McCay's early caloric restriction experiments and George Williams' concept of antagonistic pleiotropy — the idea that a gene helping an organism in youth can turn against it later in life. The piece gives particular attention to the late Mikhail Blagosklonny and his version of hyperfunction theory, who argued that aging results from "quasi-programs," developmental processes that continue running after they have finished their biological job.
"The hyperfunction framework developed by Blagosklonny, and the elegant term hyperfunction itself, provide a powerful and underappreciated lens through which to understand aging," de Magalhães explained.
Evidence Supporting a Programmatic View
The perspective walks through a growing body of experimental evidence that fits more comfortably with a programmatic view of aging than with a purely damage-based one. Single-gene manipulations have been shown to substantially extend lifespan in animal models. Reduced growth hormone and insulin-like growth factor-1 signaling slows aging in mice. Rapamycin, a drug that inhibits TOR (搜索) signaling, extends lifespan as well.
Caloric restriction receives similar treatment in the piece. De Magalhães frames it as an intervention whose benefits appear more consistent with dialing back a regulated biological process than with simply slowing the accumulation of damage.
Importantly, de Magalhães is not arguing that molecular damage does not matter. He acknowledges that it clearly contributes to diseases like cancer (搜索) and likely interacts with programmatic aging mechanisms rather than operating on an entirely separate track.
A Stepwise, Programmed Process
This programmatic view is echoed by independent research from cell biologist Junyue Cao, who heads the Laboratory of Single-Cell Genomics and Population Dynamics at Rockefeller University. Using technology that offers a systemwide view of the aging process in mice, Cao has outlined discrete stages of aging, akin to those of embryonic development, that are defined by changes in molecular signals and specific cell populations.
"The destruction of the system is programmed at a very early stage," said Cao. In humans, he suggests, the process likely begins before age 30.
Cao's work emerged from a realization that a daunting number of proteins are associated with aging, and that their effects depend on the type of cell in which they operate — a picture both more complex and more organized than the prevailing wear-and-tear model suggested.
Future Tests of the Theory
Looking forward, the perspective lays out research directions that could help settle the debate between programmatic and damage-based theories of aging. De Magalhães suggests that studying developmental biology alongside aging could reveal how the genetic programs that build, repair, and regenerate our bodies age — and how those same programs may eventually contribute to functional decline later in life.
The review gives special attention to emerging rejuvenation techniques, particularly partial cellular reprogramming. Instead of repairing accumulated molecular damage directly, this approach aims to reset a cell's biological age by changing gene regulation.
De Magalhães frames these approaches as a genuine test of hyperfunction theory. If resetting gene regulation can meaningfully restore function, that would be hard to explain under a purely damage-based model. He also suggests that identifying rejuvenation programs specific to individual tissues could eventually lead to targeted interventions that restore function — an approach that could avoid unwanted side effects, such as an increased cancer (搜索) risk, that often accompany broader anti-aging strategies.
De Magalhães is careful not to oversell where the field currently stands. Programmatic theories of aging still need rigorous experimental testing, and researchers must define their underlying molecular mechanisms and determine whether they apply to how human bodies age. The piece argues that both developmental programs and molecular damage likely shape aging, with the balance between those two forces shifting depending on the tissue and disease involved. Making sense of exactly how those two forces interact, de Magalhães argues, will require scientists to integrate developmental biology, genetics, epigenetics, and regenerative medicine — disciplines the field has not yet combined into a single, coherent picture.